Literature DB >> 18490618

The ALS/PDC syndrome of Guam and the cycad hypothesis.

John C Steele1, Patrick L McGeer.   

Abstract

There is a high incidence on Guam of a severe tauopathy known as the Parkinson- dementia complex (PDC). It is linked with an even more malignant amyotrophic lateral sclerosis (ALS) syndrome. There is great interest in determining the cause, or causes, of the Guam ALS/PDC syndrome because insight might be gained regarding ALS and the more common tauopathies found throughout the world. Research into the disorder is stimulated by hypotheses as to cause. Such hypotheses should be compatible with the known epidemiology and pathology of the syndrome. These include a high, if not exclusive, restriction to the Chamorro population, familial occurrence, a regional variation on Guam itself, a definite persistence but with declining incidence, and a possible duplication in isolated villages on the Kii peninsula of Japan. Proposed causation factors should also be able to reproduce the syndrome in experimental systems. This includes induction of neurofibrillary tangles with a tau isoform distribution similar to that of Alzheimer disease and association of the lesions with TDP-43 and Lrrk2. A recurring hypothesis as to causation is exposure to Cycas micronesica, the false Sago palm known locally as fadang. We review the reasons why this hypothesis falls short of the minimal criteria needed for further serious consideration and discuss some other possibilities that should not be excluded.

Entities:  

Mesh:

Year:  2008        PMID: 18490618     DOI: 10.1212/01.wnl.0000312571.81091.26

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

Review 1.  Fungal Neurotoxins and Sporadic Amyotrophic Lateral Sclerosis.

Authors:  Peter W French; Russell Ludowyke; Gilles J Guillemin
Journal:  Neurotox Res       Date:  2018-12-05       Impact factor: 3.911

2.  Lack of cerebral bmaa in human cerebral cortex.

Authors:  L R Snyder; R Cruz-Aguado; M Sadilek; D Galasko; C A Shaw; T J Montine
Journal:  Neurology       Date:  2009-04-14       Impact factor: 9.910

Review 3.  The epidemiology of ALS: a conspiracy of genes, environment and time.

Authors:  Ammar Al-Chalabi; Orla Hardiman
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

4.  Parkinson-dementia complex and development of a new stable isotope dilution assay for BMAA detection in tissue.

Authors:  Laura R Snyder; Reyniel Cruz-Aguado; Martin Sadilek; Douglas Galasko; Christopher A Shaw; Thomas J Montine
Journal:  Toxicol Appl Pharmacol       Date:  2009-08-28       Impact factor: 4.219

Review 5.  The phenotypic variability of amyotrophic lateral sclerosis.

Authors:  Bart Swinnen; Wim Robberecht
Journal:  Nat Rev Neurol       Date:  2014-10-14       Impact factor: 42.937

6.  Genetic Counseling Dilemmas for a Patient with Sporadic Amyotrophic Lateral Sclerosis, Frontotemporal Degeneration & Parkinson's Disease.

Authors:  Vittorio Mantero; Claudia Tarlarini; Angelo Aliprandi; Giuseppe Lauria; Andrea Rigamonti; Lucia Abate; Paola Origone; Paola Mandich; Silvana Penco; Andrea Salmaggi
Journal:  J Genet Couns       Date:  2017-03-01       Impact factor: 2.537

Review 7.  Clinical diagnosis and management of amyotrophic lateral sclerosis.

Authors:  Orla Hardiman; Leonard H van den Berg; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

Review 8.  Tauopathies as clinicopathological entities.

Authors:  David J Irwin
Journal:  Parkinsonism Relat Disord       Date:  2015-09-08       Impact factor: 4.891

9.  Regulation of FMO and PON detoxication systems in ALS human tissues.

Authors:  Stella Gagliardi; Kenneth Abel; Marika Bianchi; Pamela Milani; Stefano Bernuzzi; Manuel Corato; Mauro Ceroni; John R Cashman; Cristina Cereda
Journal:  Neurotox Res       Date:  2012-10-17       Impact factor: 3.911

Review 10.  Amyotrophic lateral sclerosis.

Authors:  Lokesh C Wijesekera; P Nigel Leigh
Journal:  Orphanet J Rare Dis       Date:  2009-02-03       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.